Testosterone Cypionate USP (Micronized) for prescription compounding, packaged in a)100g (NDC 58597-0078-6); b) 500g (NDC 58597-0078-7); c) 1000g (NDC 58597-0078-8), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327
Published February 28, 2018 · Recall initiated: February 9, 2018
Summary
FDA records drug Class II recall D-0526-2018, published February 28, 2018 and initiated February 9, 2018. Recalling firm: American Pharmaceutical Ingredients LLC; Status: Terminated; Reported quantity: 611400 g; Lot: Lot #: a) 032117A-6, Exp. 01/21/2019; 112916-2, 112916-4, Exp. 10/17/2018; b) 032117A-4, 032117A-5, Exp. 01/21/2019; 112916-1, Exp. 10/17/2018; 112916-4, Exp. 10/17/2018; c) 032117A-1, 032117A-2, 032117A-3, 032117A-4, 032117A-5, Exp. 01/21/2019; 112916-1, 112916-2, 112916-3, 112916-4, Exp. 10/17/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- American Pharmaceutical Ingredients LLC
- Distributor
- Nationwide within USA.
- Lot
- Lot #: a) 032117A-6, Exp. 01/21/2019; 112916-2, 112916-4, Exp. 10/17/2018; b) 032117A-4, 032117A-5, Exp. 01/21/2019; 112916-1, Exp. 10/17/2018; 112916-4, Exp. 10/17/2018; c) 032117A-1, 032117A-2, 032117A-3, 032117A-4, 032117A-5, Exp. 01/21/2019; 112916-1, 112916-2, 112916-3, 112916-4, Exp. 10/17/2018.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANifedipine USP for prescription compounding, packaged in a) 5g (NDC 58597-8025-2); b) 25g (NDC 58597-8025-4);February 28, 2018
- FDANaltrexone HCl USP (Dihydrate) for prescription compounding, packaged in a) 1g (NDC 58597-8407-1); b) 5g (NDCFebruary 28, 2018
- FDACalcipotriene BP (Monohydrate) for prescription compounding, packaged in a) 250mg (NDC 58597-8630-1); b) 500mgFebruary 28, 2018
- FDABaclofen USP (Micronized) for prescription compounding, packaged in a) 25g (NDC 58597-8004-4); b)100g (NDCFebruary 28, 2018
- FDATestosterone (Soy) (Micronized) USP for prescription compounding, packaged in a) 25g (NDC 58597-0077-4); b)February 28, 2018
- FDATestosterone Enanthate USP for prescription compounding, packaged in a) 25g (NDC 58597-0079-4); b) 100g (NDCFebruary 28, 2018
Questions about this recall
Was Testosterone Cypionate USP (Micronized) for prescription compounding, packaged in a)100g (NDC 58597-0078-6); b) 500g (NDC 58597-0078-7); c) 1000g (NDC 58597-0078-8), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327 recalled?
Yes. FDA published recall D-0526-2018 on February 28, 2018. Reported hazard: CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.
What should I do if I have this product?
Voluntary: Firm initiated · Letter